+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Obesity: Gut Hormone Receptors Retain Commercial Prominence

  • ID: 4778223
  • Report
  • May 2019
  • Region: Global
  • 46 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Obesity: Gut Hormone Receptors Retain Commercial Prominence

Summary

Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market’s clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline.

Scope
  • The obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets. Which drug classes are used to treat this disease? How do the drug classes in the market compare with those in the pipeline?
  • There are 267 pipeline programs in active development for obesity, respectively. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class obesity pipeline? Which first-in-class targets have been identified as most promising for obesity, and is there any overlap?
  • Which companies are the key players within the obesity market? Who has been involved in the most licensing and co-development deals for obesity products? Which first-in-class products have prior deal involvement?
Reasons to buy
  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for obesity.
  • Visualize the composition of the obesity markets in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze and compare the obesity pipeline and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class obesity pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for obesity first-in-class products.
Note: Product cover images may vary from those shown
2 of 2
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Obesity: Executive Summary
2.1 The Need for Further Novel Therapies
2.2 Pipeline Shows Increasing Innovation
2.3 Deals Landscape presents Investment Opportunities

3 Introduction
3.1 Catalyst
3.2 Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in Obesity
4.4 Epidemiology for Obesity
4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between Obesity Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
5.6 Ratio of First-in-Class Products to First-in-Class Molecular Target within the Pipeline

6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting BMPR2
6.3 Pipeline Programs Targeting BMPR1A
6.4 Pipeline Programs Targeting FADS1
6.5 Pipeline Programs Targeting BMPR1B
6.6 Pipeline Programs Targeting SLC27A2
6.7 Pipeline Programs Targeting SREBF1
6.8 Pipeline Programs Targeting ADIPOQ
6.9 Pipeline Programs Targeting C3AR1
6.10 Pipeline Programs Targeting ACACB

7 Key Players and Deals
7.1 Overview
7.1.1 Zafgen Licensing Deal with Children’s Medical Center Corporation
7.1.2 Diasome Pharmaceuticals Signs Licensing Deal with SDG
7.1.3 Evotec Co-development Deal with Eternygen

8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.3.1 Market Analysis
8.3.2 Overall Pipeline Analysis
8.3.3 First-in-Class Pipeline Analysis
8.3.4 First-in-Class Matrix Assessment
8.3.5 First-in-Class Molecular Target Evaluation
8.3.6 Key Players and Deals
8.4 About the Authors
8.4.1 Analyst
8.4.2 Therapy Area Director
8.4.3 Global Director of Therapy Analysis and Epidemiology
8.4.4 Global Head and EVP of Healthcare Operations and Strategy
8.5 About the Publisher
8.6 Contact Us
8.7 Disclaimer

List of Tables
Table 1: Nutritional status
Table 2: Obesity Total Prevalent Cases (Millions), 2012-2022

List of Figures
Figure 1: Obesity, Global Market by Molecular Target and Molecule Type, 2019
Figure 2: Obesity, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 3: Obesity Global Pipeline, by Molecular Target and Stage of Development, 2019
Figure 4: Obesity, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 5: Obesity, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 6: Obesity, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 7: Obesity, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll